Zydus Cadila has received the tentative approval from the USFDA to market Colchicine Tablets USP (US RLD - ColcyrsTM), 0.6 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
This medication is used to prevent or treat attacks of gout (also called gouty arthritis). This condition is caused by high uric acid levels in the blood. An attack of gout occurs when uric acid causes inflammation (pain, redness, swelling, and heat) in a joint. This medication is also used to prevent attacks of pain in the abdomen, chest or joints caused by a genetic auto-inflammatory disease (called as familial Mediterranean fever).
The group now has 223 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.377.3 as compared to the previous close of Rs. 380.75. The total number of shares traded during the day was 119100 in over 1378 trades.
The stock hit an intraday high of Rs. 383.9 and intraday low of 375.95. The net turnover during the day was Rs. 45354632.